menu
    • menu
    [{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Opevesostat","moa":"CYP11A1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Orion Corporation \/ Not Applicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fludrocortisone Acetate","moa":"Mineralocorticoid receptor","graph1":"Endocrinology","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Opevesostat","moa":"CYP11A1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Orion Corporation \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Orion Corporation \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"MK5684","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corporation \/ Merck & Co"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Opevesostat","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":1.9199999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.9199999999999999,"dosageForm":"","sponsorNew":"Orion Corporation \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corporation \/ Merck & Co"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Fludrocortisone Acetate","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Fludrocortisone Acetate

    Menu

    Fludrocortisone Acetate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Orion Corporation

    Finland
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Opevesostat,Dexamethasone,Fludrocortisone Acetate

    Therapeutic Area : Oncology

    Study Phase : Phase III

    Sponsor : Merck & Co

    Deal Size : $1,920.0 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Merck and Orion Mutual Option Exercise for Opevesostat in Prostate Cancer Treatment

    Details : Through the license agreement, Merck will gain global rights to develop and commercialize MK-5684 (opevesostat), which is being evaluated for metastatic castration-resistant prostate cancer.

    Product Name : MK-5684

    Product Type : Small molecule

    Upfront Cash : $290.0 million

    July 01, 2024

    Lead Product(s) : Opevesostat,Dexamethasone,Fludrocortisone Acetate

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Sponsor : Merck & Co

    Deal Size : $1,920.0 million

    Deal Type : Licensing Agreement

    Fermion Orion Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Orion Corporation

    Finland
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MK5684,Dexamethasone,Fludrocortisone Acetate

    Therapeutic Area : Oncology

    Study Phase : Phase III

    Sponsor : Merck & Co

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Orion and MSD Initiate Two Phase 3 Trials Of ODM-208 in Prostate Cancer

    Details : ODM-208/MK5684, a CYP11A1 inhibitor, is in Phase 3 trials for metastatic castration-resistant prostate cancer with hormone replacement.

    Product Name : ODM-208

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    January 05, 2024

    Lead Product(s) : MK5684,Dexamethasone,Fludrocortisone Acetate

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Sponsor : Merck & Co

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    Fermion Orion Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Orion Corporation

    Finland
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Opevesostat,Glucocorticoid,Fludrocortisone Acetate

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : MSD Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Orion and MSD Announce Global Collaboration for The Development and Commercialisation Of ODM-208, An Investiga...

    Details : ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

    Product Name : ODM-208

    Product Type : Small molecule

    Upfront Cash : $290.0 million

    July 13, 2022

    Lead Product(s) : Opevesostat,Glucocorticoid,Fludrocortisone Acetate

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : MSD Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Collaboration

    Fermion Orion Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Orion Corporation

    Finland
    Next-Gen Conjugates
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Opevesostat,Glucocorticoid,Fludrocortisone Acetate

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU

    Details : ODM-208 is a novel, oral, non-steroidal and selective inhibitor of CYP11A1 enzyme developed by Orion for the treatment of prostate cancer. ODM-208 suppresses the production of all steroid hormones and their precursors that may activate AR signalling path...

    Product Name : ODM-208

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    February 18, 2022

    Lead Product(s) : Opevesostat,Glucocorticoid,Fludrocortisone Acetate

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    Fermion Orion Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Zydus Lifesciences

    India arrow
    Conjugates Summit
    Not Confirmed

    Zydus Lifesciences

    India arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Fludrocortisone Acetate

    Therapeutic Area : Immunology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Zydus Gains Final USFDA Approval for Fludrocortisone Acetate Tablets USP, 0.1 mg

    Details : Florinef-Generic (fludrocortisone acetate) tablets are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease.

    Product Name : Florinef-Generic

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    October 17, 2024

    Lead Product(s) : Fludrocortisone Acetate

    Therapeutic Area : Immunology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    ANI Pharmaceuticals Inc

    U.S.A arrow
    Conjugates Summit
    Not Confirmed

    ANI Pharmaceuticals Inc

    U.S.A arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Fludrocortisone Acetate

    Therapeutic Area : Endocrinology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP

    Details : ANI’s Fludrocortisone Acetate Tablets are the generic version of the Reference Listed Drug (RLD) Florinef, is a prescription medicine used to treat symptoms of Addison Disease (Adrenocortical Insufficiency) and Salt-Losing Forms of Congenital Adrenogen...

    Product Name : Fludrocortisone Acetate-Generic

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    June 01, 2022

    Lead Product(s) : Fludrocortisone Acetate

    Therapeutic Area : Endocrinology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth